Neuroinflammation predicts disease progression in progressive supranuclear palsy.
Maura MalpettiLuca PassamontiPeter Simon JonesDuncan StreetTimothy RittmanTimothy D FryerYoung T HongPatricia Vàsquez RodriguezWilliam Richard Bevan-JonesFranklin I AigbirhioJohn Tiernan O'BrienJames Benedict RowePublished in: Journal of neurology, neurosurgery, and psychiatry (2021)
Molecular imaging with PET for microglial activation and tau pathology can predict clinical progression in PSP. These data encourage the evaluation of immunomodulatory approaches to disease-modifying therapies in PSP and the potential for PET to stratify patients in early phase clinical trials.
Keyphrases
- clinical trial
- end stage renal disease
- computed tomography
- newly diagnosed
- pet ct
- ejection fraction
- positron emission tomography
- lipopolysaccharide induced
- chronic kidney disease
- lps induced
- multiple sclerosis
- peritoneal dialysis
- traumatic brain injury
- inflammatory response
- pet imaging
- prognostic factors
- machine learning
- big data
- cerebrospinal fluid
- risk assessment
- patient reported outcomes
- spinal cord injury